ANTAGONISM OF **B3 ADRENOCEPTOR** FOR THE TREATMENT OF CANCER IMMUNE TOLERANCE





INVENTOR<u>S</u>: Maura Calvani Luca Filippi Pierangelo Geppetti

CO-OWNER: Azienda Ospedaliero-Universitaria MEyer

STATUS PATENT: Granted

N° PRIORITY: 102016000130491

DATE: 17 maggio 2019

Patent Family: WO2018116227A1

The invention

P


The invention relates to the use of beta-blocking compounds, in particular the antagonist of β 3 adrenoceptor (β 3-ARs), for the treatment of immune-tolerance associated with pathological states, such as cancer. The β 3 adrenoceptor, up-regulated in a hypoxic environment, recruits in the tumor microenvironment the cells involved in immune-tolerance (MDSC e Treg) replacing the cells involved in immune-competence (CD8 and NK)

The compounds of the invention allow the development of immunomodulatory drugs for oncological purposes, since they are capable to counteract the immuno-tolerance generated by tumors. In particular, the invention focuses on the role of β 3-ARs key receptors in the formation of a local and systemic micro-environment oriented towards immuno-tolerance, contributing significantly to decrease the immune system's response. The creation of selective receptor antagonists to β 3-ARs can therefore lead to the development of new drugs able to recognize, bind and inhibit the β 3-ARs receptor, so as to restore the immune-surveillance compromised by the tumor.


Images







β₃-ARs and cancer immune-tolerance




Immune-tolerant fenotype of local immune system cruitment of MDSC and Treg, replacing CD8 and NK cells)



The patented technology is designed for the development of new drugs with oncological application, for the treatment of immunotolerance in cancer.

The technology enables treatment and drug targeting, with the aim of restoring and improving immuno-surveillance in cancer patients.




Possible Developments



The patent is available for outright assignment, as well as for exclusive and nonexclusive licensing. Licenses are available for the remaining term of the patent titles.

The Research Group is available for new collaborative and third-party research activities, in-depth technical investigations, scientific advice, also aimed at raising the TRL of the technology.

The TRL of the invention is 3.



Ufficio di Trasferimento Tecnologico dell'Università degli Studi di Firenze

Sede: Piazza S. Marco 4 – 50121 Firenze

Sito web: www.unifi.it

E-mail: brevetti@unifi.it

Ufficio Regionale di Trasferimento Tecnologico

Sede: Via Luigi Carlo Farini, 8 50121 Firenze (FI)

E-mail: <u>urtt@regione.toscana.it</u>





Azienda Ospedaliero Universitaria



